RE:RE:RE:RE:RE:Financing soon There's a few things going on. Q1 should be over +$1M revenue which can land them analyst coverage. Paul has also mentioned pharma co's kicking tires recently, Kronos is shopping their IP.
This can lead to a myriad of things. My GUESS would be partnership or 3rd party investment (Cronos- Altria, AB Inbev- Tilray). There may be a log-jam of over supply in Canada but there is an established MSO cannabis industry in the US that can benefit greatly from their tech, especially if Canopy starts swinging their CO2 patents around.